Navigation Links
WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Date:9/4/2007

Earnings Conference Call to be Held on September 6, 2007 at 8:00 am

(Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Sept. 4 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or ''the Company''), the leading China- based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the second quarter ended June 30, 2007 before the US market opens on Thursday, September 6, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Thursday, September 6, 2007 to discuss its 2007 second quarter financial results and recent business activity. The conference call may be accessed by calling (US) +1 718 354 1157 / (UK) +44 (0)20 7138 0815 / (HK) +852 3002 1616. A telephone replay will be available shortly after the call until October 5, 2007 at (US) +1 718 354 1112/ (UK) +44 (0)20 7806 1970 / (HK) +852 3002 1607, Passcode: 1468987.

A live webcast of the conference call and replay will be available on the Investor Relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig

Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim

Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
2. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
3. CIOs looking to hire more IT workers in second quarter
4. DNASTAR catches second wave of sequencing
5. 9 tips for making 90 seconds count in an investment pitch
6. City of Hope adds second TomoTherapy system
7. UW-Madison hybrid-vehicle team places second nationally
8. Just one nanosecond: Clocking events at the nanoscale
9. MATCs new computer security program gears up for second semester
10. Weather Central launches second satellite
11. nPoint Secures Second Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: ... results at the International Liver Congress ("ILC") 2017 of the ... Amsterdam on the positive effects of ... model of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D ...
(Date:4/20/2017)... TIKVAH, Israel , April 20, 2017 /PRNewswire/ ... adult stem cell technologies for neurodegenerative diseases, announced today that ... the Alliance for Regenerative Medicine,s (ARM) 5 th Annual ... 2017 at 09:40 EDT in Boston . ... MHSc, Chief Medical Officer & Chief Operating Officer, will participate ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... and PUNE, India , April 19, 2017 ... Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the global market was ... by 2022, registering a CAGR of 9.6% from 2016 to 2022. ... ... ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):